# CONTENTS OF THESIS

## Abbreviations

Page No. i

## List of tables

Page No. ii

## List of figures

Page No. vi

## List of Publications

Page No. xi

### 1.0 Introduction

1.1 Modified drug delivery system  01
1.2 Biopharmaceutical Classification System  03
1.3 Selection of drug candidate for oral sustained release system  06
1.4 Design of oral sustained release system (Modified release dosage form)  10
1.5 Sustained release matrix drug delivery system (Modified release dosage form)  15
1.6 Factors affecting drug release from sustained release system  18
1.7 Melt Granulation (Wax Matrix Tablet)  19
1.8 Multilayered tablet  21
1.9 Bilayer tablet technology  23
1.10 Mechanism of drug release from SR matrix system  23
1.11 Drug release kinetic study  25
1.12 Stability study  28
1.13 Factorial Design  29
1.14 References  31

### 2.0 Literature Survey

2.1 Tramadol Hydrochloride  36
2.2 Metoprolol Succinate  37
2.3 Cyclobenzaprine Hydrochloride  39
2.4 Aceclofenac  39
2.5 Biopharmaceutics Classification System  42
2.6 Sustained release matrix system using hydrophilic polymer  42
2.7 Sustained release wax matrix system  46
2.8 Effect of excipients on release profile of drug  47
2.9 Three layer and tablet in tablet technology  48
2.10 Bilayer tablet technology  51
2.11 References  52
## CONTENTS OF THESIS

### 3.0 Drug, polymer and excipient profile
- 3.1 Drug Profile 59
- 3.2 Polymer and Excipient profile 70
- 3.3 References 92

### 4.0 Development and evaluation of modified release dosage form of tramadol HCl
- 4.1 a) List of drug, polymers and excipients 96
- 4.1 b) List of equipments 96
- 4.1 c) List of softwares used 96
- 4.2 Need of work 97
- 4.3 Plan of work 98-99
  - Experimental Part 100-114
  - Results and Discussion 115-160
- 4.4 Preformulation studies 115
- 4.5 Modified release dosage form by direct compression method 119
- 4.6 Modified release dosage form by granulation method
  - 4.6.1 Intragranulation method 121
  - 4.6.2 Extragranulation method 125
  - 4.6.3 Effect of varying concentration of drug on release profile 128
- 4.7 Modified release dosage form by wax matrix system 129
- 4.8 Effect of sintering temperature and sintering time 134
- 4.9 Modified release dosage form by three layer tablet technology 136
- 4.10 Modified release dosage form by tablet in tablet technology 140
- 4.11 Dissolution studies
  - 4.11.1 Drug release kinetics 146
  - 4.11.2 Comparison of dissolution profile 150
- 4.12 Evaluation of optimised batches of tramadol HCl
  - 4.12.1 Precompression parameters 151
  - 4.12.2 Postcompression parameters 152
- 4.13 Stability study 154
- 4.14 Optimisation study by $3^2$ factorial design 155
- 4.15 References 161

### 5.0 Development and evaluation of modified release dosage form of Metoprolol Succinate
- 5.1 a) List of drug, polymers and excipients 165
- 5.1 b) List of equipments 165
- 5.1 c) List of softwares used 165
CONTENTS OF THESIS

5.2 Need of work 166
5.3 Plan of work 167

5.4 Preformulation studies 175

5.5.1 Modified release dosage form using hydrophilic polymer system 179

5.5.2 Effect of drug concentration on release profile 186
5.6 Modified drug release from wax matrix system 187
5.7 Effect of sintering temperature and time on release profile of drug 192

5.8 Dissolution studies
5.8.1 Drug release kinetics 194
5.8.2 Comparison of dissolution profile 196

5.9 Evaluation of selected batches of Metoprolol Succinate
5.9.1 Precompression parameters 196
5.9.2 Postcompression parameters 197

5.10 Stability study 198
5.11 Optimisation study by $3^2$ factorial design 199
5.12 References 205

6.0 Development and evaluation of modified release dosage form of Cyclobenzaprine HCl

6.1 a) List of drug, polymers and excipients 209
   b) List of equipments 209

6.2 Need of work 210
6.3 Plan of work 211

6.4 Preformulation study 219
6.5 Modified drug release from hydrophilic polymer system 223
6.6 Modified drug release from wax matrix tablet 226
6.7 Effect of sintering temperature and time on release profile of drug from wax matrix system 230
6.8 Dissolution studies
6.8.1 Drug release kinetics 232
6.8.2 Comparison of dissolution profile 234

6.9 Evaluation of selected batches of Cyclobenzaprine HCl
6.9.1 Precompression parameters 234
6.9.2 Postcompression parameters 235

6.10 Stability study 236
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.11</td>
<td>Optimisation study</td>
<td>237</td>
</tr>
<tr>
<td>6.12</td>
<td>References</td>
<td>243</td>
</tr>
<tr>
<td>7.0</td>
<td>Development and evaluation of modified release dosage form of Aceclofenac</td>
<td></td>
</tr>
<tr>
<td>7.1</td>
<td>a) List of drug, polymers and excipients</td>
<td>246</td>
</tr>
<tr>
<td>7.1</td>
<td>b) List of equipments</td>
<td>246</td>
</tr>
<tr>
<td>7.1</td>
<td>c) List of softwares used</td>
<td>246</td>
</tr>
<tr>
<td>7.2</td>
<td>Need of work</td>
<td>247</td>
</tr>
<tr>
<td>7.3</td>
<td>Plan of work</td>
<td>248</td>
</tr>
<tr>
<td></td>
<td>Experimental Part</td>
<td>249-258</td>
</tr>
<tr>
<td></td>
<td>Results and Discussion</td>
<td>259-296</td>
</tr>
<tr>
<td>7.4</td>
<td>Preformulation studies</td>
<td>259</td>
</tr>
<tr>
<td>7.5</td>
<td>Modified drug release from hydrophilic polymer system</td>
<td>263</td>
</tr>
<tr>
<td>7.6</td>
<td>Modified release wax matrix system</td>
<td>270</td>
</tr>
<tr>
<td>7.7</td>
<td>Bilayer tablet technology</td>
<td>272</td>
</tr>
<tr>
<td>7.8</td>
<td>Tablet in tablet technology</td>
<td>277</td>
</tr>
<tr>
<td>7.9</td>
<td>Dissolution studies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>7.9.1 Drug release kinetics</td>
<td>279</td>
</tr>
<tr>
<td></td>
<td>7.9.2 Comparison of dissolution profile</td>
<td>282</td>
</tr>
<tr>
<td>7.10</td>
<td>Evaluation of selected formulations of Aceclofenac</td>
<td></td>
</tr>
<tr>
<td></td>
<td>7.10.1 Precompression parameters</td>
<td>282</td>
</tr>
<tr>
<td></td>
<td>7.10.2 Postcompression parameters</td>
<td>283</td>
</tr>
<tr>
<td>7.11</td>
<td>Stability study</td>
<td>284</td>
</tr>
<tr>
<td>7.12</td>
<td>Optimisation study by $3^2$ factorial design</td>
<td>285</td>
</tr>
<tr>
<td>7.13</td>
<td>References</td>
<td>297</td>
</tr>
<tr>
<td>8.0</td>
<td>Conclusion</td>
<td></td>
</tr>
<tr>
<td>8.1</td>
<td>Tramadol HCl</td>
<td>300</td>
</tr>
<tr>
<td>8.2</td>
<td>Metoprolol Succinate</td>
<td>302</td>
</tr>
<tr>
<td>8.3</td>
<td>Cyclobenzaprine HCl</td>
<td>306</td>
</tr>
<tr>
<td>8.4</td>
<td>Aceclofenac</td>
<td>309</td>
</tr>
</tbody>
</table>